Free Trial

Is it Time to Get into Merck Shares?

→ Write this ticker symbol down… (From StocksToTrade) (Ad)
Is it Time to Get into Merck Shares?

Pharmaceutical giant Merck & Co. NYSE: MRK stock exploded to the upside on news of its game-changing COVID-19 pill Molnupiravir (molnu). The interim phase three clinical trial results showed a 50% reduction in hospitalization and a 100% reduction in deaths with no severe side effects. These results were so compelling that the Company is moving forward with emergency use approval (EUA) with the FDA and has bolstered the production capacity to 10 million treatments by the end of 2021 at an estimated price of $700 per course and 10 pills per treatment/course. While COVID-19 vaccination makers initially saw their share prices fall, it turns out that vaccinations are still needed and won’t be replaced by the pill. The Company also secured a deal with the U.S. government for 1.7 million courses upon FDA approval. Australia has agreed to a 300,000-course purchase. The mere announcement sent pandemic epicenter and reopening stocks back up spiking travel, lodging, hospitality, and retail stocks. The date for the FDA advisory committee review has been set for November 30, 2021. Prudent investors looking for exposure in this COVID-19 game-changer treatment can watch for an opportunistic pullback in shares of Merck.

Q2 FY 2021 Earnings Release

On July 29, 2021, Merck released its fiscal second-quarter 2021 results for the quarter ending June 2021. The Company reported an earnings-per-share (EPS) profit of $1.31 versus $1.35 consensus analyst estimates, a (-$0.04) miss. The Company saw revenues grow 21.9% year-over-year (YoY) to $11.4 billion beating analyst estimates for $11.2 billion. Keytruda sales rose 23% YoY to $4.2 billion. Gardasil sales grew 88% to $1.2 billion. Animal Health sales rose 34% to $1.5 billion.

Conference Call Takeaways

Merck CEO, Rob Davis, set the tone, “Let me spend a moment speaking about KEYTRUDA, which again experienced very strong growth this quarter. I'm confident that KEYTRUDA will continue to be a foundational cancer therapy and achieve strong growth for years to come. We are a leader in immuno-oncology and are determined to leverage this into sustained success. We are rapidly advancing a diverse set of oncology assets, many of which we highlighted in our recent ASCO investor presentation. Across our oncology portfolio, we expect over 90 potential new indications by 2028, more than tripling our current base. We have a wide array of clinical partnerships, providing valuable insights into the biology of disease and into important potential external innovation. With our expanding oncology portfolio outside of KEYTRUDA, we will extend our leadership in cancer long into the future. I also strongly believe we will successfully navigate the eventual KEYTRUDA loss of exclusivity, given the breadth of opportunity in areas both within, as well as outside of oncology. Internally, our leaders are intensely focused on this period and efforts are underway.” He concluded, “We will be unbounded by therapeutic area, though we are mindful of the need to have a balanced portfolio over time. We'll seek new products, modalities, and platforms that allow us to establish beachheads in important areas. Our recent acquisition of Pandion and its potentially foundational immunology asset is a good example of this. We will look at both early and late-stage opportunities, and we have the financial flexibility to consider deals of all sizes, particularly given the $9 billion distribution from the Organon spinoff. And given our strong operational momentum, we are most interested in transactions that are easily integrated and less disruptive, where value is principally derived by the introduction of innovative new products that address patient needs instead of through cost energies.”

Is it Time to Get into Merck Shares?

MRK Opportunistic Pullback Levels

Using the rifle charts on the weekly and daily time frames provides a precision view of the landscape for MRK stock. The weekly rifle chart peaked out near the $84.54 Fibonacci (fib) level. Shares have since been in pullback mode. The weekly breakout is attempting to form with a rising 5-period moving average (MA) crossover at $77.13 as the weekly stochastic crosses back up. The weekly upper Bollinger Bands (BBs) sit at $70.81. The weekly market structure high (MSH) sell triggered below $86.17 while the weekly market structure low (MSL) buy triggered on the breakout through $72.05. The daily rifle chart is forming a channel tightening and potential gap fill with the falling 5-period MA at $79.03 while testing the 15-period MA overshoots at $78.76. The daily gap fill area is the $76.65 when the news was announced. Prudent investors can look for opportunistic pullback levels at $76.65 fib, $75.46 fib, $73.38 fib, $72.26 fib, $70.52 fib, and the $69.32 fib level. Upside trajectories sit at the $84.54 fib upwards to the $96.89 fib level. 

→ Truth about Trump you’ve never heard (From Porter & Company) (Ad)

Should you invest $1,000 in Merck & Co., Inc. right now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Merck & Co., Inc. (MRK)
4.4885 of 5 stars
$129.70-1.1%2.37%144.11Moderate Buy$131.33
Compare These Stocks  Add These Stocks to My Watchlist 

Jea Yu

About Jea Yu


Contributing Author

Trading Strategies


Jea Yu has been a contributing writer for MarketBeat since 2018.

Areas of Expertise

Equities, options, ETFs and futures; fundamental, qualitative, quantitative and technical analysis and pattern identification; active and swing trading; trading systems and methodology development


Bachelor of Arts, University of Maryland, College Park

Past Experience

U.S. equity markets trader, writer and analyst for over 25 years. Published four books by publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. Speaker at various expos and seminars and has been quoted and featured in USA Today, The Wall Street Journal, Traders Magazine, The Financial Times and various trade publications, including Stocks & Commodities, Active Trader and Online Investor.

Featured Articles and Offers

Search Headlines: